NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases
Author(s)
Solenne Tauty, PharmD1, Costantino De Palma, MSc2, Alexia Callet, MSc3, Dionisio Acosta-Mena, PhD4, Anouar Salhi, MSc5, Pierre-Regis Burgel, MD PhD6, Marlene Murris, MD7, Bernard Maitre, MD PhD8, François Xavier Blanc, MD PhD9, Deval Gor, MS, PhD10, Joseph Feliciano, MSc, PharmD11, Michael Loebinger, PhD BMBch MA FRCP12, Jennifer Quint, MBBS PhD13, Francoise BUGNARD, MSc14, Caroline Eteve-Pitsaer, MSc2, Charlotte Renaudat, MD15.
1Steve Consultants, Oullins, France, 2Cegedim Health data - Clinityx by GERS DATA, Boulogne-Billancourt, France, 3Cegedim Health Data UK, London, United Kingdom, 4Cegedim Health data UK, London, United Kingdom, 5steve consultants, Oullins, France, 6Hôpital Cochin AP-HP and Université Paris Cité, Paris, France, 7Service de Pneumologie, Hopital Larrey, Centre hospitalier universitaire de Toulouse, Toulouse, France, 8Centre Hospitalier Intercommunal de Créteil, University Paris Est Creteil, Créteil, France, 9Nantes Université, CHU Nantes, Service de Pneumologie, l'institut du thorax, Nantes, France, 10University of Illinois at Chicago, Union city, NJ, USA, 11Insmed Incorporated, Philadelphia, PA, USA, 12NHLI, Imperial College London, London, United Kingdom, 13School of Public Health, Imperial College London, London, United Kingdom, 14Cytel, Oullins, France, 15Cegedim Health data - Clinityx by GERS DATA, Boulogne - Billancourt cedex, France.
1Steve Consultants, Oullins, France, 2Cegedim Health data - Clinityx by GERS DATA, Boulogne-Billancourt, France, 3Cegedim Health Data UK, London, United Kingdom, 4Cegedim Health data UK, London, United Kingdom, 5steve consultants, Oullins, France, 6Hôpital Cochin AP-HP and Université Paris Cité, Paris, France, 7Service de Pneumologie, Hopital Larrey, Centre hospitalier universitaire de Toulouse, Toulouse, France, 8Centre Hospitalier Intercommunal de Créteil, University Paris Est Creteil, Créteil, France, 9Nantes Université, CHU Nantes, Service de Pneumologie, l'institut du thorax, Nantes, France, 10University of Illinois at Chicago, Union city, NJ, USA, 11Insmed Incorporated, Philadelphia, PA, USA, 12NHLI, Imperial College London, London, United Kingdom, 13School of Public Health, Imperial College London, London, United Kingdom, 14Cytel, Oullins, France, 15Cegedim Health data - Clinityx by GERS DATA, Boulogne - Billancourt cedex, France.
OBJECTIVES: The medico-economic burden of Non-Cystic Fibrosis Bronchiectasis (NCFBE) in England and France is influenced significantly by severe exacerbations requiring hospitalization. Recent data on clinical and economic burden of NCFBE is lacking, especially in France, and the generalisability of published studies from other European countries is unknown. Objectives were to compare the medico-economic burden of NCFBE hospitalizations for severe exacerbations in England and France.
METHODS: Two medico-administrative hospital databases were used separately: HES in England and PMSI in France. Patients over 12 years old hospitalized in 2022 for any acute episode with bronchiectasis and without any previous diagnosis of cystic fibrosis were included. Hospitalization characteristics and associated costs were described (mean [SD], p-value).
RESULTS: In 2022, 8,942 NCFBE hospitalized patients were included from HES and 7,621 from PMSI. Prevalence of comorbid chronic obstructive pulmonary disease (COPD) and asthma were higher in England (COPD 35% vs. 31%, p-value <0.05; Asthma 32% vs. 12%, p-value < 0.05). Length of hospitalization (days) appeared lower in England 8.5 [10.3] vs. 8.8 [8.5], p-value <0.05), as were the proportion of patients with multiple hospitalizations (8.8% vs. 10.2%, p-value <0.05) and the proportion of critical care admissions (0.6% vs. 7.2%, p-value <0.05). Cost per patient was slightly lower in England (4,260€ [2,706€] vs 4,673€ [5,772€], p-value <0.05).
CONCLUSIONS: In 2022, the costs per patient, even if they were different, were of a similar order of magnitude in England and France. However, they were affected by differences in patient management, such as shorter hospital stays in England. Variations in the weight of critical care admissions also contributed to cost differences, which may be partly explained by differences in access to such services and variations in coding practices between the two databases. Conducting such studies at the European level is essential to support medico-economic dossiers and strengthen future guidelines and recommendations.
METHODS: Two medico-administrative hospital databases were used separately: HES in England and PMSI in France. Patients over 12 years old hospitalized in 2022 for any acute episode with bronchiectasis and without any previous diagnosis of cystic fibrosis were included. Hospitalization characteristics and associated costs were described (mean [SD], p-value).
RESULTS: In 2022, 8,942 NCFBE hospitalized patients were included from HES and 7,621 from PMSI. Prevalence of comorbid chronic obstructive pulmonary disease (COPD) and asthma were higher in England (COPD 35% vs. 31%, p-value <0.05; Asthma 32% vs. 12%, p-value < 0.05). Length of hospitalization (days) appeared lower in England 8.5 [10.3] vs. 8.8 [8.5], p-value <0.05), as were the proportion of patients with multiple hospitalizations (8.8% vs. 10.2%, p-value <0.05) and the proportion of critical care admissions (0.6% vs. 7.2%, p-value <0.05). Cost per patient was slightly lower in England (4,260€ [2,706€] vs 4,673€ [5,772€], p-value <0.05).
CONCLUSIONS: In 2022, the costs per patient, even if they were different, were of a similar order of magnitude in England and France. However, they were affected by differences in patient management, such as shorter hospital stays in England. Variations in the weight of critical care admissions also contributed to cost differences, which may be partly explained by differences in access to such services and variations in coding practices between the two databases. Conducting such studies at the European level is essential to support medico-economic dossiers and strengthen future guidelines and recommendations.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE594
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)